Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines

Immunotherapy
Alexander Link, Martin F Bachmann

Abstract

Pathology in most chronic inflammatory diseases is characterized by an imbalance in cytokine expression. Targeting cytokines with monoclonal antibodies has proven to be a highly effective treatment. However, monoclonal antibody therapy has disadvantages such as high production costs, generation of antimonoclonal antibodies and the inconvenience of frequent injections. Therapeutic vaccines have the potential to overcome these limitations. The aim of active vaccination is to induce B-cell responses and obtain autoantibodies capable of neutralizing the interaction of the targeted cytokine with its receptor. In order to achieve this, therapeutic vaccines need to circumvent the potent tolerance mechanisms that exist to prevent immune responses against self-molecules. This article focuses on the tolerance mechanisms of the B- and T-cell compartments and how these may be manipulated to obtain high-affinity autoantibodies without inducing potentially dangerous autoreactive T-cell responses.

References

May 3, 1990·Nature·R M ZinkernagelH Arnheiter
Dec 1, 1994·European Journal of Immunology·M F BachmannR M Zinkernagel
Mar 1, 1995·The Journal of Experimental Medicine·C GiachinoA Lanzavecchia
Nov 26, 1993·Science·M F BachmannR M Zinkernagel
Feb 12, 1998·The Journal of Experimental Medicine·S AkkarajuC C Goodnow
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·T FehrR M Zinkernagel
Feb 24, 1999·Journal of Autoimmunity·U SteinhoffR M Zinkernagel
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·B ChackerianJ T Schiller
Mar 30, 1999·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·A GringeriD Zagury
Jul 15, 1999·Nature Biotechnology·I DalumS Mouritsen
Jan 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·M RichardJ Van Snick
Nov 9, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·G WildbaumN Karin
Mar 22, 2002·Nature Reviews. Immunology·John J O'SheaPeter Lipsky
Mar 26, 2002·Nature Reviews. Immunology·Carol L Vanderlugt, Stephen D Miller
Mar 29, 2002·European Journal of Immunology·Todd N EagarStephen D Miller
Apr 23, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Molly VernerssonLars Hellman
Nov 5, 2002·Annual Review of Immunology·Timothy K StarrKristin A Hogquist
Nov 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Bryce ChackerianJohn T Schiller
Dec 10, 2002·Annual Review of Immunology·Ronald H Schwartz
Dec 26, 2002·Annual Review of Immunology·Rolf M Zinkernagel
Jan 23, 2003·Brain : a Journal of Neurology·Roberto FurlanGianvito Martino
Jan 31, 2003·European Journal of Immunology·Andrea JegerlehnerMartin F Bachmann
Feb 5, 2003·Intervirology·Franziska LechnerMartin F Bachmann
Mar 5, 2003·Immunological Reviews·Harald von BoehmerLudger Klein
Mar 5, 2003·Annual Review of Immunology·Ralph M SteinmanMichel C Nussenzweig
Mar 29, 2003·International Immunology·David H CribbsMichael G Agadjanyan
May 27, 2003·Nature Reviews. Immunology·Ed Palmer
Aug 16, 2003·Science·Hedda WardemannMichel C Nussenzweig
Nov 5, 2003·The Journal of Experimental Medicine·Helen FerryRichard J Cornall
Nov 25, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Brett D AplinJames McCluskey
Dec 11, 2003·Nature Reviews. Drug Discovery·Martin F Bachmann, Mark R Dyer
Jan 7, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lynn Heltemes-HarrisTim Manser
Jan 28, 2004·International Archives of Allergy and Immunology·Claudia Zuany-AmorimChristoph Walker
Jun 10, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Todd N EagarStephen D Miller
Jul 21, 2004·The Journal of Experimental Medicine·Hedda WardemannMichel C Nussenzweig

❮ Previous
Next ❯

Citations

Jul 6, 2013·Dermatologic Clinics·William Abramovits, Marcial Oquendo
Feb 22, 2012·Autoimmunity Reviews·Luca SemeranoMarie-Christophe Boissier
Dec 30, 2014·European Journal of Immunology·Kiran DallenbachMartin F Bachmann
Jul 10, 2013·Human Vaccines & Immunotherapeutics·Mohey Eldin El ShikhJohn G Tew
Sep 28, 2016·BMC Immunology·Yunier Rodríguez-ÁlvarezAlicia Santos-Savio
Nov 5, 2016·Journal of Thrombosis and Haemostasis : JTH·C ZhongR Li
Apr 30, 2017·Advanced Drug Delivery Reviews·Sean H KellyJoel H Collier
Apr 21, 2021·Proceedings of the National Academy of Sciences of the United States of America·Kelly M HainlineJoel H Collier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.